News >

Understanding of MRD and CAR T-Cell Therapy in ALL Continues to Evolve

Caroline Seymour
Published: Monday, Dec 23, 2019

Rebecca B. Klisovic, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine

Rebecca B. Klisovic, MD

Minimal residual disease (MRD), or what could potentially become known as measurable residual disease, has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia (ALL), explained Rebecca B. Klisovic, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication